ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) is now up -3.24% compared to a 12-month low of $4.45. We have seen the price to move -8.2% lower and get settled at $4.48 on Oct. 26, 2017. At recent session, it appeared stuck in a range of $4.45 to $4.85. This company shares are 179.02% off its target price of $12.5 and the current market capitalization stands at $663.13M. The recent change has given its price a -24.36% deficit over SMA 50 and -43.15% deficit over its 52-week high. The stock witnessed -29.23% declines, -22.09% declines and -36.36% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found ZIOP’s volatility during a week at 6.7% and during a month it has been found around 4.49%.ZIOPHARM Oncology, Inc. (ZIOP) Top Holders
Institutional investors currently hold around $296 million or 51.2% in ZIOP stock. Look at its top three institutional owners. Third Security, Llc owns $47.38 million in ZIOPHARM Oncology, Inc., which represents roughly 7.15% of the company’s market cap and approximately 16.01% of the institutional ownership. Similar statistics are true for the second largest owner, Susquehanna International Group, Llp, which owns 7,896,778 shares of the stock are valued at $38.54 million. The third largest holder is Vanguard Group Inc, which currently holds $38.38 million worth of this stock and that ownership represents nearly 5.79% of its market capitalization.
At the end of 06/30/2017 reporting period, 59 institutional holders increased their position in ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) by some 11,088,546 shares, 48 decreased positions by 3,338,466 and 34 held positions by 46,230,457. That puts total institutional holdings at 60,657,469 shares, according to SEC filings. The stock grabbed 14 new institutional investments totaling 498,842 shares while 16 institutional investors sold out their entire positions totaling 1,619,321 shares.ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Insider Trades
Multiple company employees have indulged in significant insider trading. ZIOPHARM Oncology, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that COO, CLO, and Secretary Belbel Caesar J has sold 153,333 shares of ZIOPHARM Oncology, Inc. (ZIOP) in trading session dated Nov. 19, 2015. These shares are worth $1,968,796 and were traded at $12.84 each. The SEC filing shows that Lebel Francois performed a sale of 50,000 shares. The Executive Vice President R&D disposed these shares by way of transaction on Jun. 09, 2015. The company’s shares were given away at $10.12 per share worth to an income of some $506,000 on account of Lebel Francois.
Director, Brennan Murray, sold 40,000 common shares of ZIOPHARM Oncology, Inc. (ZIOP) in the open market. In a transaction dated Jun. 04, 2015, the shares were put up for sale at an average price of $9.7, raking in a sum of $388,000. After this sale, 12,500 common shares of ZIOP are directly owned by the insider, with total stake valued at $56,000.
In the transaction dated Jun. 03, 2015, the great number of shares disposed came courtesy the Vice Pres., Treasurer, & CAO; Lafond Kevin G disposed a total of 57,500 shares at an average price of $9.65, amounting to approximately $554,875.ZIOPHARM Oncology, Inc. (ZIOP) Analyst Guide
Several analysts have released their opinion on ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP), with 2 analysts believing it is a strong buy. Whereas 3 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2.2 average brokerage recommendation.